MK3207 for Treatment of Acute Migraines (3207-005)

A Phase IIb, Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-finding Study of MK3207 in the Treatment of Acute Migraine

The purpose of the study is to demonstrate the effectiveness and appropriate dosage level of MK3207 in the treatment of acute migraine.

Inclusion Criteria:

• Men and Women from 18 to 65 years of age
• 1+ year history of migraine that typically last from 4 to 72 hours if untreated
• Had from 2 to 8 moderate or severe migraine attacks per month in the last 2 months
• Not pregnant or planning to become pregnant in next 6 months

Exclusion Criteria:

• Pregnant or breast-feeding, or planning to become pregnant in next 6 months
• Cannot distinguish migraine attacks from tension type headaches
• Migraines are mild or resolve without medication in less than 2 hours
• More than 15 headache-days per month or have taken medication on more than 10 days per month in the last 3 months
• Basilar type or hemiplegic migraine headaches
• More than 50 years old when migraines began
• History of cardiovascular disorder within last 6 months